Brand spanking? The presumptive risks of generic antiepileptic drugs
- PMID: 21852877
- PMCID: PMC3117498
- DOI: 10.5698/1535-7511-11.2.54
Brand spanking? The presumptive risks of generic antiepileptic drugs
References
-
- Bialer M, Midha KK. Generic products of antiepileptic drugs: A perspective on bioequivalence and interchangeability. Epilepsia. 2010;51:941–950. - PubMed
-
- Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Crémieux PY. The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: The case of lamotrigine. Dis Manag. 2007;10:216–225. - PubMed
-
- Duh MS, Paradis PE, Latremouille-Viau D, Greenberg PE, Lee SP, Durkin MB, Wan GJ, Rupnow MFT, LeLorier J. The risks and costs of multiple-generic substitution of topiramate. Neurology. 2009;72:2122–2129. - PubMed
-
- Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia. 2001;42:1255–1260. - PubMed
LinkOut - more resources
Full Text Sources
